Living Legends in Psychopharmacology 2026, Translating Neuroscience, Precision Medicine, and AI into Breakthrough Treatment for Complex Psychiatric Disorders

Add to Calendar Living Legends in Psychopharmacology 2026, Translating Neuroscience, Precision Medicine, and AI into Breakthrough Treatment for Complex Psychiatric Disorders 4/17/2026 8:15:00 AM 4/18/2026 5:30:00 PM America/New_York For More Details: https://miami.cloud-cme.com/course/courseoverview?EID=18634 Description: Join world-renowned leaders in the field for a transformative two-day conference at the leading edge of psychiatric innovation. Living Legends in Psychopharmacology 2026 brings together pioneering minds to explore the frontiers of neuroscience, precision medicine, and AI – translating cutting-edge discoveries into real-world strategies for even the most complex, treatment-resistant cases. Designed to b... Sunny Isles Beach Hotel, Sunny Isles Beach, FL false MM/DD/YYYY


Date & Location
Friday, April 17, 2026, 8:15 AM - Saturday, April 18, 2026, 5:30 PM, Sunny Isles Beach Hotel, Sunny Isles Beach, FL, Sunny Isles Beach , FL

Target Audience
Specialties - Psychiatry
Professions - General Neurologist, Internist, Medical Student, Neurosurgeon, Non-Physician, Nurse, Nurse Practitioner, Pediatric Neurologist, Physician, Physician Assistant, Psychiatrist, Psychologist, Resident

Credits
AMA PRA Category 1 Credits™ (15.00 hours), APA Credit(s) (15.00 hours), Non-Physician Attendance (15.00 hours)

Overview
Join world-renowned leaders in the field for a transformative two-day conference at the leading edge of psychiatric innovation. Living Legends in Psychopharmacology 2026 brings together pioneering minds to explore the frontiers of neuroscience, precision medicine, and AI – translating cutting-edge discoveries into real-world strategies for even the most complex, treatment-resistant cases. Designed to be both visionary and clinically grounded, this immersive experience offers deep dives into Personalized Psychiatry, including pharmacogenomics, blood level monitoring, and pharmacokinetic tailoring to optimize medication sequencing and dosing. Attendees will explore next-generation treatments such as ketamine, ECT, TMS, and psychedelic-assisted therapies, as well as multimodal augmentation strategies for refractory mood and psychotic disorders. Foundational sessions in Neurobiology will examine core systems of neurotransmission, receptor dynamics, gene-environment interplay, and epigenetic regulation – providing a scientific framework for truly individualized care. Targeted modules on Schizophrenia, Bipolar Disorder, and Mood Disorders will focus on early intervention, treatment resistance, and emerging pharmacologic innovations. Additional sessions will cover the latest in Anxiety and PTSD, including critical discussions on benzodiazepine stewardship and promising novel agents. A dedicated focus on Special Populations – spanning women’s mental health, pediatric and geriatric psychiatry, and autism spectrum disorders – ensures a breadth of relevance across the clinical landscape. Attendees will also deepen their understanding of Sleep and Substance Use Disorders, exploring neurobiological mechanisms and evolving therapeutic approaches. Furthermore, a timely and thought-provoking session on the Ethical Use of AI in Psychiatry will address data privacy, algorithmic bias, and how artificial intelligence can support – rather than supplant – the essential human connection at the heart of psychiatric care. Anchored in real-world case discussions, interactive panels, and unparalleled access to field-defining experts, this course equips clinicians with the insights, tools, and science to meet the demands of 21st-century psychiatry – where complexity is the norm, and precision is the goal.

ACCME Objectives
  1. Apply principles of personalized psychiatry—including pharmacogenomic testing, blood level monitoring, and drug-drug interaction analysis—to optimize psychotropic medication regimens in treatment-resistant patients.
  2. Evaluate and implement evidence-based use of cutting-edge therapies such as ketamine, ECT, TMS, and psychedelic-assisted treatments in the management of mood and psychotic disorders.
  3. Integrate current neurobiological insights—including neurotransmitter systems, receptor signaling, and gene-environment interactions—into the diagnosis and treatment planning of complex psychiatric conditions.
  4. Differentiate treatment strategies for schizophrenia and bipolar disorder, including approaches for prodromal states, first-episode psychosis, and long-term management of chronic or refractory illness.
  5. Select and sequence appropriate pharmacologic and somatic treatments for major depressive disorder based on pathophysiologic mechanisms such as inflammation, neuroplasticity, and stress response systems.
  6. Formulate individualized treatment plans for anxiety disorders and PTSD, incorporating both traditional pharmacotherapy and emerging modalities like ketamine and psychedelic-assisted psychotherapy.
  7. Design safe and effective psychopharmacologic treatment strategies for women across the reproductive lifespan, with consideration for hormonal fluctuations, pregnancy, and postpartum care.
  8. Interpret and apply recent findings in pediatric, adolescent, and geriatric psychiatry to inform age-appropriate diagnosis, medication selection, and monitoring strategies.
  9. Assess and treat autism spectrum disorders using advanced pharmacologic approaches grounded in the latest research on neurodevelopment and neurobiology.
  10. Diagnose and manage sleep disorders and substance use disorders with a focus on neurobiological mechanisms, risk mitigation, and integrated pharmacologic and behavioral treatments.

APA Objectives
  1. Apply principles of personalized psychiatry—including pharmacogenomic testing, blood level monitoring, and drug-drug interaction analysis—to optimize psychotropic medication regimens in treatment-resistant patients.
  2. Evaluate and implement evidence-based use of cutting-edge therapies such as ketamine, ECT, TMS, and psychedelic-assisted treatments in the management of mood and psychotic disorders.
  3. Integrate current neurobiological insights—including neurotransmitter systems, receptor signaling, and gene-environment interactions—into the diagnosis and treatment planning of complex psychiatric conditions.
  4. Differentiate treatment strategies for schizophrenia and bipolar disorder, including approaches for prodromal states, first-episode psychosis, and long-term management of chronic or refractory illness.
  5. Select and sequence appropriate pharmacologic and somatic treatments for major depressive disorder based on pathophysiologic mechanisms such as inflammation, neuroplasticity, and stress response systems.
  6. Formulate individualized treatment plans for anxiety disorders and PTSD, incorporating both traditional pharmacotherapy and emerging modalities like ketamine and psychedelic-assisted psychotherapy.
  7. Design safe and effective psychopharmacologic treatment strategies for women across the reproductive lifespan, with consideration for hormonal fluctuations, pregnancy, and postpartum care.
  8. Interpret and apply recent findings in pediatric, adolescent, and geriatric psychiatry to inform age-appropriate diagnosis, medication selection, and monitoring strategies.
  9. Assess and treat autism spectrum disorders using advanced pharmacologic approaches grounded in the latest research on neurodevelopment and neurobiology.
  10. Diagnose and manage sleep disorders and substance use disorders with a focus on neurobiological mechanisms, risk mitigation, and integrated pharmacologic and behavioral treatments.

Accreditation
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

The University of Miami Leonard M. Miller School of Medicine designates this Live Activity for a maximum of 15.00 of AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME


Additional Information

Cancellation Policy

Cancellations received in writing no less than 20 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to University of [email protected].

University of Miami Healthcare System reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

Accessibility Statement
 
University of Miami Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.



Keywords: LIVEAPA